Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Mineralys Therapeutics, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Mineralys Therapeutics held its 2026 annual stockholder meeting on May 21, 2026, where shareholders elected three Class III directors and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, demonstrating strong governance continuity and investor confidence.
Key Takeaways
Three directors elected to Class III positions with three-year terms expiring in 2029: Srinivas Akkaraju M.D., Ph.D., Brian Taylor Slingsby M.D., Ph.D., M.P.H., and Daphne Karydas
Daphne Karydas received the highest vote count at 66,626,766 votes, indicating strong shareholder support for the slate
2 more takeaways